Datamonitor’s OTC Pharmaceuticals - North America (NAFTA) Industry Guide is an essential resource for top-level data and analysis covering the OTC Pharmaceuticals industry in each of the North American Free Trade Agreement (United States, Canada, and Mexico) countries. The report includes easily comparable data on market value, volume, segmentation and market share, plus full five year market forecasts. It examines future problems, innovations and potential growth areas within the market.
Scope of the Report
* Contains an executive summary and data on value, volume and segmentation
* Provides textual analysis of the industry’s prospects, competitive landscape and profiles of the leading companies
* Incorporates in-depth five forces competitive environment analysis and scorecards
* Compares data from the US, Canada and Mexico, alongside individual chapters on each country. .
* Includes a five-year forecast of the industry
Highlights
The NAFTA OTC Pharmaceuticals market reaches a value of $31760.1 million in 2009.
The US is the leading country among the NAFTA bloc, with market revenues of $27540.7 million in 2009
Mexico was the fastest growing country, with a CAGR of 6.4% over the 2005–2009 period.
Why you should buy this report
* Spot future trends and developments
* Inform your business decisions
* Add weight to presentations and marketing materials
* Save time carrying out entry-level research
Market Definition
The OTC pharmaceuticals market consists of the retail sale of traditional medicines, cough and cold preparations (tablets, mixtures, lozenges, topical remedies, inhalers), vitamins and minerals (multi-vitamins, single minerals, single vitamins, tonics, cod liver oil), indigestion preparations (tablets, powders, mixtures), analgesics (Paracetamol, Ibuprofen, Aspirinand other analgesics), and medicated skin products (anti-bacteria’s, acne treatments, anti-fungal, disinfectants and other), topical OTC medicines (anesthetic products, anti-itch products, antibiotic creams/gels), plasters & bandages (adhesive bandages/plasters, first aid tape, gauze pads/rolled gauze, liquid bandages and other tape or bandage), first aid kits and other (anti-smoking aids, rectal medications, eye/ear drops, sleeping aids, and motion sickness).
About Datamonitor 2
11
What is this report about? 11
Who is the target reader? 11
How to use this report 11
Definitions 11
NAFTA Countries OTC Pharmaceuticals Industry Outlook 12
OTC Pharmaceuticals in Canada 18
Market overview 18
Market value 19
Market segmentation I 20
Market segmentation II 21
Market share 22
Five forces analysis 23
Leading companies 31
Market Forecasts 45
Market distribution 47
Macroeconomic indicators 48
OTC Pharmaceuticals in Mexico 50
Market overview 50
Market value 51
Market segmentation I 52
Market segmentation II 53
Market share 54
Five forces analysis 55
Leading companies 63
Market Forecasts 83
Market distribution 85
Macroeconomic indicators 86
OTC Pharmaceuticals in the United States 88
Market overview 88
Market value 89
Market segmentation I 90
Market segmentation II 91
Market share 92
Five forces analysis 93
Leading companies 101
Market Forecasts 117
Market distribution 119
Macroeconomic indicators 120
APPENDIX 122
Data Research Methodology 122
LIST OF TABLES
Table 1: NAFTA countries otc pharmaceuticals industry, revenue ($m), 2005–14 13
Table 2: NAFTA countries otc pharmaceuticals industry, revenue ($m), 2005–09 15
Table 3: NAFTA countries otc pharmaceuticals industry forecast, revenue ($m), 2009–14 17
Table 4: Canada otc pharmaceuticals market value: $ million, 2005–09 19
Table 5: Canada otc pharmaceuticals Market segmentation I:% share, by value, 2009 20
Table 6: Canada otc pharmaceuticals Market segmentation II: % share, by value, 2009 21
Table 7: Canada otc pharmaceuticals market share: % share, by value, 2009 22
Table 8: Johnson & Johnson: key facts 31
Table 9: Johnson & Johnson: key financials ($) 34
Table 10: Johnson & Johnson: key financial ratios 35
Table 11: GlaxoSmithKline Plc: key facts 37
Table 12: GlaxoSmithKline Plc: key financials ($) 40
Table 13: GlaxoSmithKline Plc: key financials (£) 40
Table 14: GlaxoSmithKline Plc: key financial ratios 40
Table 15: Jamieson Laboratories: key facts 43
Table 16: Canada OTC pharmaceuticals market value forecast: $ million, 2009–14 45
Table 17: Canada otc pharmaceuticals market distribution: % share, by value, 2009 47
Table 18: Canada size of population (million), 2005–09 48
Table 19: Canada gdp (constant 2000 prices, $ billion), 2005–09 48
Table 20: Canada gdp (current prices, $ billion), 2005–09 48
Table 21: Canada inflation, 2005–09 49
Table 22: Canada consumer price index (absolute), 2005–09 49
Table 23: Canada exchange rate, 2005–09 49
Table 24: Mexico otc pharmaceuticals market value: $ million, 2005–09 51
Table 25: Mexico otc pharmaceuticals Market segmentation I:% share, by value, 2009 52
Table 26: Mexico otc pharmaceuticals Market segmentation II: % share, by value, 2009 53
Table 27: Mexico otc pharmaceuticals market share: % share, by value, 2009 54
Table 28: Bayer AG: key facts 63
Table 29: Bayer AG: key financials ($) 67
Table 30: Bayer AG: key financials (€) 68
Table 31: Bayer AG: key financial ratios 68
Table 32: Johnson & Johnson: key facts 71
Table 33: Johnson & Johnson: key financials ($) 74
Table 34: Johnson & Johnson: key financial ratios 75
Table 35: Boehringer Ingelheim GmbH: key facts 77
Table 36: Boehringer Ingelheim GmbH: key financials ($) 79
Table 37: Boehringer Ingelheim GmbH: key financials (€) 80
Table 38: Boehringer Ingelheim GmbH: key financial ratios 80
Table 39: Mexico OTC pharmaceuticals market value forecast: $ million, 2009–14 83
Table 40: Mexico otc pharmaceuticals market distribution: % share, by value, 2009 85
Table 41: Mexico size of population (million), 2005–09 86
Table 42: Mexico gdp (constant 2000 prices, $ billion), 2005–09 86
Table 43: Mexico gdp (current prices, $ billion), 2005–09 86
Table 44: Mexico inflation, 2005–09 87
Table 45: Mexico consumer price index (absolute), 2005–09 87
Table 46: Mexico exchange rate, 2005–09 87
Table 47: United States otc pharmaceuticals market value: $ million, 2005–09 89
Table 48: United States otc pharmaceuticals Market segmentation I:% share, by value, 2009 90
Table 49: United States otc pharmaceuticals Market segmentation II: % share, by value, 2009 91
Table 50: United States otc pharmaceuticals market share: % share, by value, 2009 92
Table 51: Johnson & Johnson: key facts 101
Table 52: Johnson & Johnson: key financials ($) 104
Table 53: Johnson & Johnson: key financial ratios 105
Table 54: Pfizer: key facts 107
Table 55: Pfizer: key financials ($) 109
Table 56: Pfizer: key financial ratios 109
Table 57: Procter & Gamble Company, The: key facts 112
Table 58: Procter & Gamble Company, The: key financials ($) 114
Table 59: Procter & Gamble Company, The: key financial ratios 115
Table 60: United States OTC pharmaceuticals market value forecast: $ million, 2009–14 117
Table 61: United States otc pharmaceuticals market distribution: % share, by value, 2009 119
Table 62: United States size of population (million), 2005–09 120
Table 63: United States gdp (constant 2000 prices, $ billion), 2005–09 120
Table 64: United States gdp (current prices, $ billion), 2005–09 120
Table 65: United States inflation, 2005–09 121
Table 66: United States consumer price index (absolute), 2005–09 121
Table 67: United States exchange rate, 2005–09 121
LIST OF FIGURES
Figure 1: NAFTA countries otc pharmaceuticals industry, revenue ($m), 2005–14 12
Figure 2: NAFTA countries otc pharmaceuticals industry, revenue ($m), 2005–09 14
Figure 3: NAFTA countries otc pharmaceuticals industry forecast, revenue ($m), 2009–14 16
Figure 4: Canada otc pharmaceuticals market value: $ million, 2005–09 19
Figure 5: Canada otc pharmaceuticals Market segmentation I:% share, by value, 2009 20
Figure 6: Canada otc pharmaceuticals Market segmentation II: % share, by value, 2009 21
Figure 7: Canada otc pharmaceuticals market share: % share, by value, 2009 22
Figure 8: Forces driving competition in the otc pharmaceuticals market in Canada, 2009 23
Figure 9: Drivers of buyer power in the otc pharmaceuticals market in Canada, 2009 25
Figure 10: Drivers of supplier power in the otc pharmaceuticals market in Canada, 2009 26
Figure 11: Factors influencing the likelihood of new entrants in the otc pharmaceuticals market in Canada, 2009 27
Figure 12: Factors influencing the threat of substitutes in the otc pharmaceuticals market in Canada, 2009 29
Figure 13: Drivers of degree of rivalry in the otc pharmaceuticals market in Canada, 2009 30
Figure 14: Johnson & Johnson: revenues & profitability 35
Figure 15: Johnson & Johnson: assets & liabilities 36
Figure 16: GlaxoSmithKline Plc: revenues & profitability 41
Figure 17: GlaxoSmithKline Plc: assets & liabilities 42
Figure 18: Canada OTC pharmaceuticals market value forecast: $ million, 2009–14 46
Figure 19: Canada otc pharmaceuticals market distribution: % share, by value, 2009 47
Figure 20: Mexico otc pharmaceuticals market value: $ million, 2005–09 51
Figure 21: Mexico otc pharmaceuticals Market segmentation I:% share, by value, 2009 52
Figure 22: Mexico otc pharmaceuticals Market segmentation II: % share, by value, 2009 53
Figure 23: Mexico otc pharmaceuticals market share: % share, by value, 2009 54
Figure 24: Forces driving competition in the otc pharmaceuticals market in Mexico, 2009 55
Figure 25: Drivers of buyer power in the otc pharmaceuticals market in Mexico, 2009 57
Figure 26: Drivers of supplier power in the otc pharmaceuticals market in Mexico, 2009 58
Figure 27: Factors influencing the likelihood of new entrants in the otc pharmaceuticals market in Mexico, 2009 59
Figure 28: Factors influencing the threat of substitutes in the otc pharmaceuticals market in Mexico, 2009 61
Figure 29: Drivers of degree of rivalry in the otc pharmaceuticals market in Mexico, 2009 62
Figure 30: Bayer AG: revenues & profitability 69
Figure 31: Bayer AG: assets & liabilities 70
Figure 32: Johnson & Johnson: revenues & profitability 75
Figure 33: Johnson & Johnson: assets & liabilities 76
Figure 34: Boehringer Ingelheim GmbH: revenues & profitability 81
Figure 35: Boehringer Ingelheim GmbH: assets & liabilities 82
Figure 36: Mexico OTC pharmaceuticals market value forecast: $ million, 2009–14 84
Figure 37: Mexico otc pharmaceuticals market distribution: % share, by value, 2009 85
Figure 38: United States otc pharmaceuticals market value: $ million, 2005–09 89
Figure 39: United States otc pharmaceuticals Market segmentation I:% share, by value, 2009 90
Figure 40: United States otc pharmaceuticals Market segmentation II: % share, by value, 2009 91
Figure 41: United States otc pharmaceuticals market share: % share, by value, 2009 92
Figure 42: Forces driving competition in the otc pharmaceuticals market in the United States, 2009 93
Figure 43: Drivers of buyer power in the otc pharmaceuticals market in the United States, 2009 95
Figure 44: Drivers of supplier power in the otc pharmaceuticals market in the United States, 2009 96
Figure 45: Factors influencing the likelihood of new entrants in the otc pharmaceuticals market in the United States, 2009 97
Figure 46: Factors influencing the threat of substitutes in the otc pharmaceuticals market in the United States, 2009 99
Figure 47: Drivers of degree of rivalry in the otc pharmaceuticals market in the United States, 2009 100
Figure 48: Johnson & Johnson: revenues & profitability 105
Figure 49: Johnson & Johnson: assets & liabilities 106
Figure 50: Pfizer: revenues & profitability 110
Figure 51: Pfizer: assets & liabilities 111
Figure 52: Procter & Gamble Company, The: revenues & profitability 115
Figure 53: Procter & Gamble Company, The: assets & liabilities 116
Figure 54: United States OTC pharmaceuticals market value forecast: $ million, 2009–14 118
Figure 55: United States otc pharmaceuticals market distribution: % share, by value, 2009 119
Other selected research from the 'Canada' category:
OTC Pharmaceuticals - North America (NAFTA) Industry Guide
Pharmaceuticals: Canada Industry Guide
Other selected research from the 'Mexico' category:
McEvoy and Farmer's Complete Guide to IVD Distribution in Mexico
Personal Hygiene/ Personal Care: Mexico Industry Guide
Other selected research from the 'USA' category:
US Pharmaceutical Market Outlook 2011-2021
Do you want to know the effects of the Obama government’s legislation for US healthcare? Insurance coverage will be extended... Learn More
US Biotech Market Analysis
Other selected research from the 'OTC' category:
OTC Pharmaceuticals: Advanced Emerging Markets (Brazil, Hungary, Mexico, Poland, South Africa, Taiwan) Industry Guide
Personal Hygiene/ Personal Care: France Industry Guide